Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:ABT
- CUSIP: 00282410
- Web: www.abbott.com
Capitalization:- Market Cap: $90.16 billion
- Outstanding Shares: 1,737,443,000
Average Prices:- 50 Day Moving Avg: $50.14
- 200 Day Moving Avg: $47.04
- 52 Week Range: $37.38 - $52.60
P/E:- Trailing P/E Ratio: 72.68
- Foreward P/E Ratio: 18.67
- P/E Growth: 1.86
Sales & Book Value:- Annual Revenue: $23.61 billion
- Price / Sales: 3.82
- Book Value: $18.19 per share
- Price / Book: 2.85
Dividend:- Annual Dividend: $1.06
- Dividend Yield: 2.1%
Profitability:- EBIDTA: $5.14 billion
- Net Margins: 4.96%
- Return on Equity: 14.43%
- Return on Assets: 6.47%
Debt:- Debt-to-Equity Ratio: 0.75%
- Current Ratio: 2.94%
- Quick Ratio: 2.41%
Misc:- Average Volume: 5.27 million shs.
- Beta: 1.06
- Short Ratio: 2.35
Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, September 15th. Shareholders of record on Friday, October 13th will be given a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 dividend on an annualized basis and a yield of 2.04%. The ex-dividend date is Thursday, October 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Thursday, July, 20th. The company reported $0.62 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.60 by $0.02. The firm had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The business's quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.55 EPS. View Abbott Laboratories' Earnings History.
When will Abbott Laboratories make its next earnings announcement?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its third quarter earnings guidance on Thursday, July, 20th. The company provided earnings per share guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.
Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?
12 brokerages have issued 1 year target prices for Abbott Laboratories' stock. Their forecasts range from $42.00 to $58.00. On average, they anticipate Abbott Laboratories' share price to reach $53.25 in the next twelve months. View Analyst Ratings for Abbott Laboratories.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Catalent (CTLT), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO) and Akorn (AKRX).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Miles D. White, Chairman of the Board, Chief Executive Officer
- Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
- Michael T. Rousseau, President - Cardiovascular and Neuromodulation
- Hubert L. Allen, Executive Vice President, General Counsel, Secretary
- Stephen R. Fussell, Executive Vice President - Human Resources
- Brian J. Blaser, Executive Vice President - Diagnostics Products
- John M. Capek Ph.D., Executive Vice President - Ventures
- Robert B. Ford, Executive Vice President - Medical Devices
- Heather L. Mason, Executive Vice President - Nutritional Products
- Roger Bird, Senior Vice President - U.S. Nutrition
Who owns Abbott Laboratories stock?
Abbott Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.48%), BlackRock Inc. (6.01%), State Street Corp (4.43%), Capital Research Global Investors (2.74%), Bank of New York Mellon Corp (1.94%) and Northern Trust Corp (1.55%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?
Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Fort Washington Investment Advisors Inc. OH, FMR LLC, Macquarie Group Ltd., BlackRock Inc., Prudential PLC and DnB Asset Management AS. Company insiders that have sold Abbott Laboratories stock in the last year include Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?
Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Janus Henderson Group PLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Boston Partners, Principal Financial Group Inc., Parametric Portfolio Associates LLC and Hexavest Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy Abbott Laboratories stock?
Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of Abbott Laboratories stock can currently be purchased for approximately $51.89.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $53.25 (2.62% upside) |
Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/1/2017 | BMO Capital Markets | Reiterated Rating | Hold | $53.00 | N/A |  |
| 8/17/2017 | Citigroup Inc. | Initiated Coverage | Neutral -> Neutral | $53.00 | Medium | |
| 8/17/2017 | Cowen and Company | Reiterated Rating | Buy | $55.00 | Medium | |
| 8/3/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $58.00 | Low | |
| 7/22/2017 | Barclays PLC | Reiterated Rating | Overweight | $52.00 -> $57.00 | Low | |
| 7/21/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $58.00 | Low | |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | | Low | |
| 6/30/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $47.50 -> $54.00 | Low | |
| 6/29/2017 | Guggenheim | Initiated Coverage | Buy | $58.00 | Low | |
| 6/21/2017 | BTIG Research | Initiated Coverage | Buy | $56.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral -> Neutral | $45.00 | Low | |
| 5/15/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | | Low | |
| 9/19/2016 | Bank of America Corporation | Reiterated Rating | Buy | | N/A | |
| 8/9/2016 | Deutsche Bank AG | Reiterated Rating | Buy | | N/A | |
| 7/28/2016 | Argus | Reiterated Rating | Buy | $55.00 | N/A | |
| 6/21/2016 | Edward Jones | Upgrade | Hold -> Buy | | N/A | |
| 6/8/2016 | Credit Suisse Group | Reiterated Rating | Buy | | N/A | |
| 4/30/2016 | S&P Equity Research | Reiterated Rating | Hold | | N/A | |
| 4/30/2016 | Gabelli | Reiterated Rating | Buy | | N/A | |
| 4/28/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | | N/A | |
| 4/14/2016 | First Global | Downgrade | Outperform -> Marketperform | | N/A | |
| 3/28/2016 | Leerink Swann | Boost Price Target | Market Perform | $37.00 -> $40.00 | N/A | |
| 1/29/2016 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $46.00 -> $42.00 | N/A | |
| 1/29/2016 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Abbott Laboratories (NYSE:ABT)Earnings History by Quarter for Abbott Laboratories (NYSE ABT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/17/2017 | | $0.66 | | | | | N/A | |
| 7/20/2017 | Q2 2017 | $0.60 | $0.62 | $6.63 billion | $6.64 billion | View | N/A | |
| 4/19/2017 | 3/31/2017 | $0.43 | $0.48 | $6.16 billion | $6.34 billion | View | N/A | |
| 1/25/2017 | Q416 | $0.64 | $0.65 | $5.41 billion | $5.33 billion | View | Listen | |
| 10/19/2016 | Q316 | $0.58 | $0.59 | $5.29 billion | $5.30 billion | View | Listen | |
| 7/20/2016 | Q216 | $0.53 | $0.55 | $5.24 billion | $5.30 billion | View | Listen | |
| 4/20/2016 | Q116 | $0.39 | $0.41 | $4.77 billion | $4.90 billion | View | Listen | |
| 1/28/2016 | Q415 | $0.61 | $0.62 | $5.31 billion | $5.20 billion | View | Listen | |
| 10/21/2015 | Q315 | $0.53 | $0.54 | $5.16 billion | $5.15 billion | View | Listen | |
| 7/22/2015 | Q215 | $0.50 | $0.52 | $5.15 billion | $5.20 billion | View | Listen | |
| 4/22/2015 | Q115 | $0.42 | $0.47 | $4.85 billion | $4.90 billion | View | Listen | |
| 1/29/2015 | Q414 | $0.68 | $0.71 | $5.48 billion | $5.36 billion | View | Listen | |
| 10/22/2014 | Q314 | $0.60 | $0.62 | $5.62 billion | $5.10 billion | View | Listen | |
| 7/16/2014 | Q214 | $0.51 | $0.54 | $5.53 billion | $5.55 billion | View | Listen | |
| 4/16/2014 | Q114 | $0.36 | $0.41 | $5.29 billion | $5.24 billion | View | Listen | |
| 1/22/2014 | Q413 | $0.58 | $0.58 | $5.72 billion | $5.66 billion | View | Listen | |
| 10/16/2013 | Q313 | $0.52 | $0.55 | $5.46 billion | $5.37 billion | View | Listen | |
| 7/17/2013 | Q2 2013 | $0.44 | $0.46 | $5.53 billion | $5.45 billion | View | Listen | |
| 4/17/2013 | Q1 2013 | $0.41 | $0.42 | $5.42 billion | $5.38 billion | View | Listen | |
| 1/23/2013 | Q4 2012 | $1.50 | $1.51 | $10.58 billion | $10.80 billion | View | Listen | |
| 10/17/2012 | | $1.28 | $1.30 | | | View | N/A | |
| 7/18/2012 | | $1.22 | $1.23 | | | View | N/A | |
| 4/18/2012 | | $1.00 | $1.03 | | | View | N/A | |
| 1/25/2012 | | $1.44 | $1.45 | | | View | N/A | |
| 10/19/2011 | | $1.17 | $1.18 | | | View | N/A | |
| 7/20/2011 | | $1.12 | $1.12 | | | View | N/A | |
| 4/20/2011 | | $0.90 | $0.91 | | | View | N/A | |
| 1/26/2011 | | $1.29 | $1.30 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Abbott Laboratories (NYSE:ABT)2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.83
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.43 | $0.50 | $0.45 |
| Q2 2017 | 3 | $0.59 | $0.61 | $0.60 |
| Q3 2017 | 3 | $0.64 | $0.68 | $0.66 |
| Q4 2017 | 3 | $0.72 | $0.73 | $0.73 |
| Q1 2018 | 2 | $0.55 | $0.56 | $0.56 |
| Q2 2018 | 2 | $0.69 | $0.71 | $0.70 |
| Q3 2018 | 2 | $0.74 | $0.76 | $0.75 |
| Q4 2018 | 2 | $0.80 | $0.84 | $0.82 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Abbott Laboratories (NYSE:ABT)| Next Dividend: | 11/15/2017 |
| Annual Dividend: | $1.06 |
| Dividend Yield: | 2.04% |
| Dividend Growth: | 22.90% (3 Year Average) |
| Payout Ratio: | 149.30% (Trailing 12 Months of Earnings)
42.57% (Based on This Year's Estimates)
38.13% (Based on Next Year's Estimates)
|
| Track Record: | 44 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Abbott Laboratories (NYSE ABT)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 9/15/2017 | quarterly | $0.27 | 2.05% | 10/12/2017 | 10/13/2017 | 11/15/2017 |
| 6/9/2017 | quarterly | $0.27 | 2.25% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.27 | 2.36% | 4/11/2017 | 4/14/2017 | 5/15/2017 |
| 12/9/2016 | quarterly | $0.27 | 2.7% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/15/2016 | quarterly | $0.26 | 2.48% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/10/2016 | quarterly | $0.26 | 2.75% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.26 | 2.66% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 12/11/2015 | quarterly | $0.26 | 2.32% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/17/2015 | quarterly | $0.24 | 2.22% | 10/13/2015 | 10/15/2015 | 11/15/2015 |
| 6/12/2015 | quarterly | $0.24 | 2% | 7/13/2015 | 7/15/2015 | 8/15/2015 |
| 2/20/2015 | quarterly | $0.24 | 2.03% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 12/12/2014 | quarterly | $0.24 | 2.21% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/11/2014 | quarterly | $0.22 | 2.07% | 10/10/2014 | 10/15/2014 | 11/15/2014 |
| 6/13/2014 | quarterly | $0.22 | 2.21% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/21/2014 | quarterly | $0.22 | 2.26% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 10/16/2013 | quarterly | $0.22 | 2.37% | 1/13/2014 | 1/15/2014 | 2/15/2014 |
| 9/12/2013 | quarterly | $0.14 | 1.61% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/14/2013 | quarterly | $0.14 | 1.52% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.14 | 1.61% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 12/14/2012 | quarterly | $0.14 | 0.86% | 1/11/2013 | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.50%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/16/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $49.50 | $9,729,225.00 | |
| 8/1/2017 | Sharon J Bracken | Insider | Sell | 2,000 | $49.16 | $98,320.00 | |
| 7/27/2017 | Brian J Blaser | Insider | Sell | 15,000 | $50.00 | $750,000.00 | |
| 7/25/2017 | Hubert L Allen | Insider | Sell | 4,600 | $50.79 | $233,634.00 | |
| 6/15/2017 | Jared Watkin | Insider | Sell | 552 | $47.97 | $26,479.44 | |
| 6/8/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $46.00 | $9,041,300.00 | |
| 4/27/2017 | Roger Bird | Insider | Sell | 5,600 | $43.82 | $245,392.00 | |
| 4/26/2017 | Joseph J Manning | Insider | Sell | 4,200 | $43.95 | $184,590.00 | |
| 3/1/2017 | Michael J. Warmuth | Insider | Sell | 3,851 | $45.39 | $174,796.89 | |
| 2/23/2017 | Robert E Funck | VP | Sell | 25,500 | $45.50 | $1,160,250.00 | |
| 2/22/2017 | Roger Bird | Insider | Sell | 13,222 | $45.02 | $595,254.44 | |
| 2/21/2017 | Deepak S Nath | Insider | Sell | 319 | $44.98 | $14,348.62 | |
| 1/31/2017 | Heather L Mason | Insider | Sell | 35,700 | $40.77 | $1,455,489.00 | |
| 12/20/2016 | Brian J Blaser | Insider | Buy | 15,580 | $38.45 | $599,051.00 | |
| 12/14/2016 | Robert B Ford | Insider | Buy | 12,775 | $39.09 | $499,374.75 | |
| 11/10/2016 | Miles D White | Chairman | Buy | 121,456 | $40.45 | $4,912,895.20 | |
| 11/1/2016 | Sally E Blount | Director | Buy | 5,100 | $39.24 | $200,124.00 | |
| 9/26/2016 | Daniel Gesua Sive Salvadori | SVP | Sell | 815 | $41.71 | $33,993.65 | |
| 7/28/2016 | Stephen R Fussell | Insider | Sell | 41,500 | $45.00 | $1,867,500.00 | |
| 7/26/2016 | Michael J Warmuth | Insider | Sell | 26,800 | $43.49 | $1,165,532.00 | |
| 7/25/2016 | Miles D White | Chairman | Buy | 242,547 | $43.18 | $10,473,179.46 | |
| 7/25/2016 | Robert E Funck | VP | Sell | 26,800 | $43.08 | $1,154,544.00 | |
| 6/28/2016 | Hubert L Allen | EVP | Sell | 3,400 | $37.14 | $126,276.00 | |
| 6/15/2016 | Jared Watkin | SVP | Sell | 552 | $37.63 | $20,771.76 | |
| 6/1/2016 | Brian B Yoor | CFO | Sell | 565 | $39.49 | $22,311.85 | |
| 4/28/2016 | Deepak S Nath | SVP | Sell | 53 | $41.31 | $2,189.43 | |
| 3/31/2016 | Jaime Contreras | SVP | Sell | 462 | $41.78 | $19,302.36 | |
| 2/29/2016 | Brian B Yoor | CFO | Sell | 865 | $39.12 | $33,838.80 | |
| 2/29/2016 | Deepak S Nath | SVP | Sell | 793 | $39.27 | $31,141.11 | |
| 2/29/2016 | Robert B Ford | EVP | Sell | 1,706 | $39.28 | $67,011.68 | |
| 2/29/2016 | Robert E Funck | VP | Sell | 1,333 | $39.30 | $52,386.90 | |
| 2/22/2016 | Jared Watkin | SVP | Sell | 554 | $39.09 | $21,655.86 | |
| 2/16/2016 | Deepak S. Nath | SVP | Sell | 171 | $37.13 | $6,349.23 | |
| 12/16/2015 | Miles D. White | CEO | Sell | 438,000 | $46.00 | $20,148,000.00 | |
| 8/18/2015 | Stephen R. Fussell | EVP | Sell | 13,096 | $50.46 | $660,824.16 | |
| 4/27/2015 | Heather L Mason | EVP | Sell | 13,500 | $47.45 | $640,575.00 | |
| 4/27/2015 | Roger Bird | SVP | Sell | 28,548 | $47.57 | $1,358,028.36 | |
| 3/26/2015 | J. Scott White | SVP | Sell | 12,483 | $46.68 | $582,706.44 | |
| 3/2/2015 | Jaime Contreras | SVP | Sell | 9,209 | $47.34 | $435,954.06 | |
| 2/4/2015 | John M Capek | EVP | Sell | 34,292 | $45.66 | $1,565,772.72 | |
| 11/25/2014 | Jaime Contreras | SVP | Sell | 51,600 | $44.07 | $2,274,012.00 | |
| 10/29/2014 | Miles D White | CEO | Sell | 440,800 | $42.52 | $18,742,816.00 | |
| 3/3/2014 | John Landgraf | EVP | Sell | 17,293 | $39.38 | $680,998.34 | |
| 3/3/2014 | Katherine Doyle | SVP | Sell | 6,639 | $39.01 | $258,987.39 | |
| 3/3/2014 | Robert Funck | VP | Sell | 1,413 | $38.97 | $55,064.61 | |
| 2/18/2014 | John Landgraf | EVP | Sell | 1,583 | $39.10 | $61,895.30 | |
| 1/29/2014 | Michael Warmuth | EVP | Sell | 11,430 | $36.21 | $413,880.30 | |
| 12/6/2013 | Jean-Yves Pavee | SVP | Sell | 5,855 | $37.46 | $219,328.30 | |
| 11/7/2013 | Stephen Fussell | EVP | Sell | 10,466 | $37.59 | $393,416.94 | |
| 10/30/2013 | Jaime Contreras | SVP | Sell | 25,368 | $36.85 | $934,810.80 | |
| 6/7/2013 | Heather L Mason | SVP | Sell | 12,000 | $37.01 | $444,120.00 | |
| 2/1/2013 | William A Osborn | Director | Buy | 10,000 | $33.86 | $338,600.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
| Source: |
|
| Date | Headline |
|---|
 | Abbott Hosts Conference Call for Third-Quarter Earnings
finance.yahoo.com - September 20 at 3:18 PM |
 | Buy Abbott Laboratories - Cramer's Lightning Round (9/15/17) - Seeking Alpha
seekingalpha.com - September 18 at 8:35 PM |
 | IWB, SLB, ABT, UNP: Large Outflows Detected at ETF
www.nasdaq.com - September 18 at 3:33 PM |
| Abbott Laboratories’ 375th Consecutive Quarterly Dividend
finance.yahoo.com - September 18 at 3:33 PM |
 | Abbott Laboratories (ABT) Expected to Post Quarterly Sales of $6.71 Billion
www.americanbankingnews.com - September 18 at 9:40 AM |
| Abbott Laboratories (ABT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 17 at 9:02 AM |
| Zacks: Brokerages Anticipate Abbott Laboratories (ABT) to Post $0.65 Earnings Per Share
www.americanbankingnews.com - September 16 at 6:12 AM |
 | Alibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round - TheStreet.com
www.thestreet.com - September 15 at 11:41 PM |
| Abbott Laboratories (ABT) Announces Quarterly Dividend of $0.27
www.americanbankingnews.com - September 15 at 5:52 PM |
| Head-To-Head Contrast: Abbott Laboratories (ABT) versus Its Peers
www.americanbankingnews.com - September 14 at 8:28 PM |
| Abbott Declares 375th Consecutive Quarterly Dividend
finance.yahoo.com - September 14 at 3:19 PM |
| FreeStyle® Libre Flash Glucose Monitoring Technology Gains Reimbursement Approval from the United Kingdom's National Health Service
finance.yahoo.com - September 14 at 1:33 AM |
 | 3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) - Investorplace.com
investorplace.com - September 12 at 3:23 PM |
| Can Abbott Top Its All-Time High?
seekingalpha.com - September 7 at 8:20 PM |
| Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
finance.yahoo.com - September 7 at 3:19 PM |
| Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index (DJSI)
finance.yahoo.com - September 7 at 3:19 PM |
| ETFs with exposure to Abbott Laboratories : September 7, 2017
finance.yahoo.com - September 7 at 3:19 PM |
| Abbott Laboratories :ABT-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 3:29 PM |
| Abbott Laboratories (ABT) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - September 2 at 10:38 AM |
| Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod - Nasdaq
www.nasdaq.com - September 1 at 3:44 PM |
| Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm
finance.yahoo.com - September 1 at 3:44 PM |
| Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod
finance.yahoo.com - September 1 at 3:44 PM |
| Revolutionary Glucose Monitoring Technology FreeStyle® Libre Now Reimbursed Across Japan
finance.yahoo.com - August 31 at 3:20 PM |
| Abbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking - TheStreet.com
www.thestreet.com - August 30 at 8:24 PM |
 | Abbott software updates aim to fix pacemaker battery issues, hacking risks
www.marketwatch.com - August 30 at 3:22 PM |
| Abbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking
finance.yahoo.com - August 30 at 3:21 PM |
| Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns
finance.yahoo.com - August 30 at 3:21 PM |
| Abbott Laboratories (ABT) Expected to Announce Quarterly Sales of $6.71 Billion
www.americanbankingnews.com - August 30 at 5:34 AM |
| Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm - Nasdaq
www.nasdaq.com - August 29 at 8:46 PM |
| Analysts’ Recommendations for Pfizer in August 2017
finance.yahoo.com - August 29 at 8:46 PM |
| Abbott Releases New Software Updates for Pacemakers
finance.yahoo.com - August 29 at 8:46 PM |
| Top Momentum Picks In Blue-Chip Health Care
seekingalpha.com - August 29 at 3:45 PM |
| Top Momentum Picks In Blue-Chip Health Care
seekingalpha.com - August 29 at 3:45 PM |
 | Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
www.zacks.com - August 29 at 3:45 PM |
| Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
www.zacks.com - August 29 at 3:45 PM |
| Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
finance.yahoo.com - August 29 at 3:45 PM |
| Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
finance.yahoo.com - August 29 at 3:45 PM |
| Abbott releases new round of cyber updates for St. Jude pacemakers
finance.yahoo.com - August 29 at 3:45 PM |
| Abbott releases new round of cyber updates for St. Jude pacemakers
finance.yahoo.com - August 29 at 3:45 PM |
| Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts
finance.yahoo.com - August 29 at 3:45 PM |
| Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts
finance.yahoo.com - August 29 at 3:45 PM |
| FDA Approves Abbott Heart Device, Stock Rises - TheStreet.com
www.thestreet.com - August 28 at 8:37 PM |
 | Technical Snapshots for These Medical Equipment Stocks -- Abbott Labs, Boston ...
www.prnewswire.com - August 28 at 3:34 PM |
| Abbott Introduces HeartMate 3 Left Ventricular Assist System - the Latest Milestone In Therapy For Advanced Heart Failure Patients
finance.yahoo.com - August 28 at 3:34 PM |
| The Top 5 Healthcare Dividend Stocks Today
seekingalpha.com - August 23 at 10:11 PM |
| Abbott Laboratories – Value Analysis (NYSE:ABT) : August 23, 2017
finance.yahoo.com - August 23 at 10:10 PM |
| Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : August 23, 2017
finance.yahoo.com - August 23 at 3:21 PM |
| Abbott Laboratories : ABT-US: Dividend Analysis : July 14th, 2017 (record date) : By the numbers : August 23, 2017
finance.yahoo.com - August 23 at 3:21 PM |
| Abbott Laboratories (ABT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 23 at 9:16 AM |
| Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - August 21 at 8:34 PM |
Abbott Laboratories (ABT) Chart for Wednesday, September, 20, 2017
